P012 First multicenter evaluation of initial experience and short-term follow-up of cerebral aneurysms treated with the Trenza Embolization device

<h3>Introduction</h3> Intrasaccular devices are an increasingly recognized option in endovascular therapy of cerebral aneurysms, in particular in wide-necked and ruptured aneurysms. The Trenza Embolization Device (TED) is a novel intrasaccular device. Literature about TED is scarce, as the prospective post-market multicenter study TREAT is currently still recruiting. <h3>Aim of Study</h3> To evaluate first experience and short-term follow-up (FU) of the novel TED in the therapy of cerebral aneurysms. <h3>Methods</h3> Retrospective multicenter analysis of 25 aneurysms (3 ruptured) in 25 patients (18 females, mean age 62.4 years) treated with TED. Succesful deployment of the device, necessity of adjunct devices, complications, occlusion according to Raymond-Roy occlusion classification (RROC), initially and at first FU after treatment were evaluated. <h3>Results</h3> Initial selected TED was successfully implanted in 24/25 (96%) cases. In 6/25 (24%) aneurysms two TED were implanted. In two (8%) cases adjunct devices were necessary, in one case stent-assistance, and in another both balloon- and stent-assistance. Except symptomatic thrombembolic event in one (4%) case, no further relevant complications were observed. Initial occlusion was RROC I in 12 (48%), and RROC II in 13 (52%) cases. In 17 cases FU (mean 6, range 3-11 months) was available, showing occlusion RROC I, and RROC II in each 8 (47%) cases, while one aneurysm (6%) with initially RROC II showed relevant reperfusion (RROC III) with indication to re-therapy. <h3>Conclusion</h3> The results of this first retrospective, multicenter analysis of the novel TED appear promising. Further prospective, multicenter studies with larger patient cohorts, and long-term FU are neccessary. <h3>Disclosure of Interest</h3> no.